Suppr超能文献

伦博瑞生用于治疗中国患者失眠症:四例病例研究

Lemborexant for the Treatment of Insomnia in Patients From China: Four Case Studies.

作者信息

Jian Weiying, Feng Minyan, Li Jin

机构信息

Department of Mental Health, Guangzhou United Family Hospital, Guangzhou, CHN.

Department of Pharmacy, Guangzhou United Family Hospital, Guangzhou, CHN.

出版信息

Cureus. 2024 Jul 16;16(7):e64655. doi: 10.7759/cureus.64655. eCollection 2024 Jul.

Abstract

Lemborexant is a competitive antagonist of dual orexin receptors indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance that occur at least three nights per week for ≥3 months, although there is adequate opportunity for sleep. There has been no published study of its efficacy and safety in treating patients from China with insomnia. In this case report, we present four adult patients from China with insomnia who were successfully treated with add-on lemborexant or switched from benzodiazepines or Z-drugs to lemborexant. None of the four patients experienced any discomforts related to lemborexant use. In conclusion, lemborexant treatment was effective and safe in treating the four patients from China with insomnia in this case report, and more studies are warranted to further assess the efficacy and safety of lemborexant in treating patients from China with insomnia.

摘要

伦博瑞生是一种双重食欲素受体竞争性拮抗剂,适用于治疗成年失眠患者,这些患者的特征为入睡困难和/或睡眠维持困难,每周至少出现三个晚上,持续≥3个月,尽管有充足的睡眠机会。目前尚无关于其治疗中国失眠患者有效性和安全性的已发表研究。在本病例报告中,我们介绍了四名来自中国的成年失眠患者,他们通过加用伦博瑞生或从苯二氮䓬类药物或Z类药物转换为伦博瑞生而成功得到治疗。这四名患者均未出现与使用伦博瑞生相关的任何不适。总之,在本病例报告中,伦博瑞生治疗对四名来自中国的失眠患者有效且安全,需要更多研究以进一步评估伦博瑞生治疗中国失眠患者的有效性和安全性。

相似文献

1
Lemborexant for the Treatment of Insomnia in Patients From China: Four Case Studies.
Cureus. 2024 Jul 16;16(7):e64655. doi: 10.7759/cureus.64655. eCollection 2024 Jul.
3
Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder.
Neurol Ther. 2024 Aug;13(4):1081-1098. doi: 10.1007/s40120-024-00622-9. Epub 2024 May 15.
5
Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder.
Postgrad Med. 2022 Apr;134(3):316-325. doi: 10.1080/00325481.2022.2049553. Epub 2022 Mar 20.
6
Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
J Manag Care Spec Pharm. 2021 Sep;27(9):1296-1308. doi: 10.18553/jmcp.2021.21011. Epub 2021 Jun 12.
7
Evaluating lemborexant for the treatment of insomnia.
Expert Opin Pharmacother. 2021 Jul;22(10):1235-1243. doi: 10.1080/14656566.2021.1902987. Epub 2021 Apr 20.

引用本文的文献

本文引用的文献

1
Emerging and upcoming therapies in insomnia.
Transl Clin Pharmacol. 2024 Mar;32(1):1-17. doi: 10.12793/tcp.2024.32.e5. Epub 2024 Mar 25.
4
Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease.
Annu Rev Pharmacol Toxicol. 2024 Jan 23;64:359-386. doi: 10.1146/annurev-pharmtox-040323-031929. Epub 2023 Sep 14.
5
Efficacy and safety of lemborexant in subjects previously treated with placebo for 6 months in a randomized phase 3 study.
Sleep Med. 2023 Oct;110:111-119. doi: 10.1016/j.sleep.2023.07.023. Epub 2023 Jul 27.
7
Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users.
J Clin Psychopharmacol. 2022;42(4):365-373. doi: 10.1097/JCP.0000000000001561. Epub 2022 Jun 24.
8
Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder.
Sleep Med X. 2022 Mar 24;4:100044. doi: 10.1016/j.sleepx.2022.100044. eCollection 2022 Dec.
9
Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder.
Postgrad Med. 2022 Apr;134(3):316-325. doi: 10.1080/00325481.2022.2049553. Epub 2022 Mar 20.
10
Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder.
Sleep Med. 2022 Feb;90:249-257. doi: 10.1016/j.sleep.2022.01.024. Epub 2022 Feb 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验